eli lilly retatrutide study Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lilly retatrutide Phase 3

GLP1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss

Appetite suppression helps with weight loss, but it can also change food preferences

Nutrition, digestion, whole-food support and metabolism underpin sustainable health

Weight loss can feel discouraging when your body seems to be working against you

Building or maintaining a consistent exercise routine before starting medication means you will not need to establish new habits while also adjusting to medication effects

BOOST unveiled its new BOOST Advanced Nutritional Shake designed to support nutritional needs during a weight management journey for adults who are on GLP-1s, the company says